contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nexstim-plc-agreed-on-a-loan-with-nordea-to-fund-investments-into-growth

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Selvom I mener, at Brainlab med vilje flytter handler til 2026, så tag venligst i betragtning, at hospitalernes budgetter er stramme og årsspecifikke. Hvis pengene er afsat til 2025, vil de blive brugt i 2025 og ikke udskudt. En anden sag er den private sektor, og der er pengebrugen friere.

Interessant at danskerne også taler om behandling af OCD, mens OCD er ‘Nej’ for Nexstim i tabellen i slutningen af denne sammenligning af TMS-enheder, udført af en klinik i Florida.                   floridatmsclinic.com – 21 Sep 25              TMS Devices Review | Side By Side Comparison Table    A complete overview of TMS devices with head-to-head comparison, including NeuroStar, BrainsWay, MagStim, MagVenture, NexStim, Apollo, Ultimate and Blossom.

Det er helt klart blevet fortalt, at den garanterede salgsmargin fortsætter også i de kommende år. Mængden af den vil dog stige med nye godkendelser. Her kan du direkte se det sted i interviewet, hvor sagen behandles: https://youtu.be/8u1-gw34P9w?si=c0441lw-1aJQbC4E&t=1230

Jeg husker ikke sådan en meddelelse fra Karvinen, men jeg synes, denne begrundelse er mere fornuftig end den pludselige ophør af butikkernes informationsdeling. Også toldroderiet har sikkert delvist boostet handlen, selvom direktøren sagde, at dette havde en lille, hvis ikke ubetydelig, vægt. Stadig et gyldigt salgsargument. Et øjeblik kiggede jeg allerede på lån fra banken, men jeg tror, jeg stadig holder mig til min linje. For meget spekulation og for lidt fakta til, at jeg ville foretage træk i nogen retning. Omsætningen er stadig lille, og udsving i stille perioder er normalt.

Jeg har selv gættet på, at man i slutningen af året også har kunnet fokusere på mange NBS6-opdateringer, som ikke overskrider informationsgrænsen. I år har Nexstim dog annonceret ret mange handler tidligere end normalt. Direktøren meddelte, så vidt jeg husker, ved en begivenhed i sommer/efterår, at det ville være mere fordelagtigt for kunden at bestille udstyret dengang (før NBS6-godkendelsen) med det samme + med en NBS6-opdateringsmulighed, end at vente/udskyde hele anskaffelsen af udstyret, indtil man kunne få et NBS6-godkendt udstyr senere. Dette kunne forklare de fænomener, der er set i år (mange ordrer annonceret allerede om sommeren, når ordremeddelelser normalt kommer i december eller ved årsskiftet, samt en indtil videre stille slutning på året med hensyn til meddelelser). Eller så er Brainlab 4 mio. Det nødvendige salg er allerede opfyldt med ordrer for 2025, og Brainlab har ingen interesse i at lukke flere handler i 2025. Hvis handlerne kan flyttes et par uger direkte ind i 2026, så kan Brainlab begynde at opfylde salgsmålene for 2026 med dem (der er dog ikke informeret noget om, hvorvidt lignende er aftalt for 2026, men jeg ville anse det for et helt muligt scenarie, at der også er aftalt et minimumssalg for 2026).

Man er jo lidt spændt på, hvad der kommer derfra, når intet bliver annonceret. Man får lyst til at tilføje, men hvad nu hvis.. Den er allerede nu en af de største i porteføljen. På den anden side ser fremtiden under alle omstændigheder lovende ud. En pæn stigning er i vente, hvis der kommer handel bare som forventet.

Jeg så det samme lige før. Jeg er kommet til den konklusion, at ingen handler vil blive annonceret fra december. Ellers kan f.eks. Brainlabs andel af salget beregnes så tydeligt ud fra dem. (Hvis den information skulle beskyttes). Og igen, hvis kun én eller to egne handler annonceres, vil det virkelig skabe panik blandt investorerne. Jeg har et sted over ti tusind aktier, og jeg bliver ombord.

Nexstim

Company Announcement, Helsinki, 10 August 2023 at 2 PM (EEST) Nexstim Plc agreed on a loan with Nordea to fund investments into growth Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has agreed...

Company Announcement, Helsinki, 10 August 2023 at 2 PM (EEST) Nexstim Plc agreed on a loan with Nordea to fund investments into growth Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has agreed on a loan totalling EUR 1.5 million with Nordea Bank. The Company plans to use the loan to fund its strategic investments as well as growth and working capital needs. The loan is to be withdrawn in full during August 2023. The loan period is five years and other loan conditions are usual. Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO +358 9 2727 170 <a href="https://www.globenewswire.com/Tracker?data=z_SM13ATB14Ipc_Lvosz_9pfmVKuIy-DrBU1ijJi5ihruQb_gb3BSghyoC5RalN3-eACT5Wp-CPCiXrILNbbc0ElfcV-B6exB8K0_zNCdmpBQHdTNdhA5KWFQQ64bjuh">mikko.karvinen@nexstim.com</a> The Company’s Certified Advisor is Erik Penser Bank. About Nexstim Plc Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain. Nexstim shares are listed on Nasdaq First North Growth Market Finland. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=TJlQXV7h8p8_dq2TAA5NmCQWezAy_9UWa0mF0fnFD_khZxFgfDVzJ8gTIDHc3dcyj6Vg50WPcJ0CnDydenuf-w==">www.nexstim.com</a> Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/d17d0eb3-c872-4037-99b0-38c04e6892db">Nexstim Plc_Company announcement_Loan_10082023_FINAL_EN</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMDgzNDA3MiM0MDE1OTMyNzcjMjAxNjIwNg=="> <img src="https://ml-eu.globenewswire.com/media/ZjVhOGNkMWYtN2M3Zi00NGZkLTg2MWMtMzM0NTk1MTNiZmI3LTEwMjc3Nzk=/tiny/Nexstim-Oyj.png">